Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine Learning Approach With Real-world Data

12. november 2026 opdateret af: Novartis Pharmaceuticals

Characterising the Elevated Liver Enzymes in Ribociclib (Kisqali®) Treatment Among Patients With HR+ HER2- Advanced Breast Cancer Using a Machine Learning Approach With Real-world Data

The aim of this study is to assess key factors associated with response and non-response to the current established management algorithm for elevated liver enzymes (ELE) following ribociclib treatment in hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (aBC) patients in real world settings in the United States (US). The data for this study will be drawn from a US-based breast cancer specific electronic health record (EHR) database.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Anslået)

8001

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Novartis Pharmaceuticals

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Adult patients in the US with a diagnosis of HR+/HER2- aBC and evidence of ribociclib use.

Beskrivelse

Inclusion criteria:

  1. Evidence of diagnosis of Stage IV breast cancer (aBC) as per American Joint Committee on Cancer (AJCC), 8th Edition during study period
  2. Aged 18 years or older at the index date
  3. Have at least one prescription for Ribociclib
  4. Have lab values available for alanine aminotransferase/aspartate aminotransferase (ALT/AST) at baseline, and up to 6 months post-baseline (at least one measurement at baseline and one measurement during follow up)

Exclusion criteria:

  1. Missing values for patient ID or age
  2. No available lab data for liver enzymes (ALT/AST) at either baseline or up to 6 months post-baseline

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: RETROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Ribociclib Treatment Responders

Patients who undergo a management action (dose reduction or temporary suspension) and achieve recovery to ≤ baseline grade ALT/AST within 60 days without permanent treatment discontinuation or treatment switch.

Ribociclib Treatment Non-responders

Patients who undergo a management action (dose reduction or temporary suspension) but whose ALT/AST level does not recover to baseline grade within 60 days, experience a worsening grade, recurrence after rechallenge, permanent treatment discontinuation or switch to another systemic therapy.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients by Demographics and Clinical Characterisitcs
Tidsramme: Baseline

Demographics and clinical characteristics include age group, sex, race, ethnicity, geographical location, insurance type, socioeconomic status (SES) index (1 = lowest SES, 2, 3, 4, 5 = highest SES), menopausal status, smoking status, year of breast cancer (BC) diagnosis, type of BC, biomarker status, Eastern Cooperative Oncology (ECOG) performance status (0 = fully active, 1, 2, 3, 4 = completely disabled) number of metastatic sites, site of metastasis, chemotherapy status, radiation status, surgery status, and comorbidities.

Baseline
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Age at Ribociclib Initiation
Tidsramme: Baseline
Baseline
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Duration of Follow-up
Tidsramme: Up to approximately 12 months
Up to approximately 12 months
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Body Weight
Tidsramme: Baseline
Baseline
Among aBC Patients Who Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Charlson Comorbidity Index (CCI)
Tidsramme: Baseline

CCI is a weighted index that takes into account both the number and the seriousness of comorbid conditions. Each condition is assigned a weighted score, and the scores are summed to generate a total CCI score. Total scores range from 0 to 37, with higher scores reflecting a greater burden of disease and an increased risk of mortality.

Baseline

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients by Demographics and Clinical Characterisitcs
Tidsramme: Baseline

Demographics and clinical characteristics include age group, sex, race, ethnicity, geographical location, insurance type, SES index (1 = lowest SES, 2, 3, 4, 5 = highest SES), menopausal status, smoking status, year of BC diagnosis, type of BC, biomarker status, ECOG performance status (0 = fully active, 1, 2, 3, 4 = completely disabled) number of metastatic sites, site of metastasis, chemotherapy status, radiation status, surgery status, and comorbidities.

Baseline
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Age at Ribociclib Initiation
Tidsramme: Baseline
Baseline
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Duration of Follow-up
Tidsramme: Up to approximately 12 months
Up to approximately 12 months
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Body Weight
Tidsramme: Baseline
Baseline
Among aBC Patients Who do not Develop ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, CCI
Tidsramme: Baseline
Baseline
Among aBC Patients Who Experience a First ≥ Grade 2 ALT/AST Elevation Within the First 6 Months Following Ribociclib Treatment Initiation, Number of Patients With Subsequent Episodes of ALT/AST Elevation
Tidsramme: Up to approximately 12 months
Up to approximately 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

13. november 2026

Primær færdiggørelse (Anslået)

1. januar 2027

Studieafslutning (Anslået)

1. januar 2027

Datoer for studieregistrering

Først indsendt

12. november 2026

Først indsendt, der opfyldte QC-kriterier

12. november 2026

Først opslået (Faktiske)

18. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner